Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Executive Summary

Things couldn't have gone any worse for Bristol-Myers Squibb's Opdivo in the CheckMate 026 lung cancer data presented at ESMO. Without even a trend towards efficacy in patients with high levels of PD-L1 expression, imminent erosion of market share by Merck's Keytruda seems inevitable.

Advertisement

Related Content

Another Opdivo Disappointment For BMS, This Time In Kidney Cancer
AstraZeneca Hopes Imfinzi Breakthrough Get Can Burn Off MYSTIC Failure
Soriot Stands By His Post-Pfizer Sales Pledge For AstraZeneca
Post-MYSTIC, Bristol Renews CTLA-4 Vows, But Is "Not Wedded" In Lung Cancer
MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC
Keeping Track: Immuno-Oncology Racks Up More Approvals; Bar Still Too High For Advair Generics
Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities
ESMO Preview: Opdivo Under Pressure
Does CheckMate 026 Take Bristol Out Of The End Game?
What's Next For Bristol's Opdivo/Yervoy Combination

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel